Logo (PRNewsfoto/TransCode Therapeutics, Inc.) Several patients ... a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. TransCode's 2023 Phase ...

Q32 Bio Logo (PRNewsfoto/Q32 Bio) "We have conviction that bempikibart is differentiated from existing AA therapies and has the potential to transform the treatment paradigm for this disease. This is ...

Logo (PRNewsfoto/TransCode Therapeutics, Inc.) Several patients in the first ... a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. TransCode's 2023 ...

As Elon Musk moves to shutter the U.S. Agency for International Development, the agency’s support for the discovery of novel ...

The FDA recently granted EXG-34217 Rare Pediatric Disease Designation (RPDD) and Regenerative Medicine Advanced Therapy (RMAT) Designation.

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on SWTX: SpringWorks Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte's Flow Electroporation ® technology and ExPERT ™ platform.

Writer David Goyer (Foundation, The Dark Knight trilogy, Blade) has created Emergence, a world meant to be the first franchise on a new platform called Incention, which connects fans to expand and ...

Goyer has set up a sci-fi franchise titled “Emergence” at Incention, a new platform that aims to “bring AI and blockchain to Hollywood, and redefine how modern franchises are developed.” ...

TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers.

The global Gene Therapy market, valued at US$7.21 billion in 2023, is forecasted to grow at a robust CAGR of 19.4%, reaching ...

TransCode Therapeutics (RNAZ) shares are rising after dosing the first patient in Cohort 3 of its Phase 1 trial for lead candidate TTX-MC138 No significant safety issues were reported in previous ...